Thermal behavior and phase identification of Valsartan by standard and temperature-modulated differential scanning calorimetry

Drug Development and Industrial Pharmacy

Volumn 39, Issue 10, 2013, Pages 1508-1514

  Skotnicki, Marcin ^a   Gaweł, Agnieszka ^a   Cebe, Peggy ^b   Pyda, Marek ^a,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b TUFTS UNIVERSITY   (United States)

^c RZESZOW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Amorphous form; Differential scanning calorimetry; Thermal analysis; Thermogravimetry; TMDSC; Valsartan; XRPD

Indexed keywords

VALSARTAN;

ARTICLE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STABILITY; ENTHALPY; FLOW RATE; GLASS TRANSITION TEMPERATURE; HEAT; TEMPERATURE SENSITIVITY; THERMODYNAMICS; THERMOGRAVIMETRY; X RAY DIFFRACTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG STABILITY; HOT TEMPERATURE; PHASE TRANSITION; POWDER DIFFRACTION; POWDERS; REPRODUCIBILITY OF RESULTS; TETRAZOLES; THERMOGRAVIMETRY; VALINE;

EID: 84883698660     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.704379     Document Type: Article

References (21)

1. Nabel EG. (2003). Cardiovascular disease. N Engl J Med, 349:60-72. (Pubitemid 36765105)
2. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index. html. Accessed on: June 2011.
3. Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J. (1993). Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol, 110:761-771. (Pubitemid 23279290)
4. Dina R, Jafari M. (2000). Angiotensin II-receptor antagonists: An overview. Am J Health Syst Pharm, 57:1231-1241. (Pubitemid 30441381)
5. Ripley TL. (2005). Valsartan in chronic heart failure. Ann Pharmacother, 39:460-469. (Pubitemid 40270913)
6. Sweetman SC, ed. (2011). Martindale: The complete drug reference. London: Pharmaceutical Press. Available at: www.medicinescomplete.com. Accessed on: June 2011.
7. Pfeffer-Hennig S, Piechon P, Bellus M, Goldbronn C, Tedesco E. (2004). Physico-chemical characterization of an active pharmaceutical ingredient: Crystal polyorphism and structrual analysis. J Therm Anal Calor, 77:663-679.
8. Bond L, Allen S, Davies MC, Roberts CJ, Shivji AP, Tendler SJ et al. (2002). Differential scanning calorimetry and scanning thermal microscopy analysis of pharmaceutical materials. Int J Pharm, 243:71-82.
9. Craig D Q M, Reading M. (2006). Thermal analysis of pharmaceuticals. 1st ed. New York: CRC Press.
10. Bynum KC. (2011). Preformulation and early phase method development. In: Ahuja S, Scypinski S, eds. Handbook of Modern Pharmaceutical Analysis (Separation Science and Technology). 2nd ed. Waltham: Academic Press, 361-396.
11. Niazi SK. (2007). The scope of preformulation studies. In: Niazi SK, ed. Handbook of Preformulation Chemical, Biological, and Botanical Drugs. 1st ed. New York: Informa Healthcare, 57. 86.
12. Ibrahim HK, El-Setouhy DA. (2010). Valsartan orodispersible tablets: Formulation, in vitro/in vivo characterization. AAPS PharmSciTech, 11:189.196.
13. Shrivastava AR, Ursekar B, Kapadia CJ. (2009). Design, optimization, preparation and evaluation of dispersion granules of valsartan and formulation into tablets. Curr Drug Deliv, 6:28.37.
14. Wunderlich B. (2005). Thermal analysis of polymeric materials. Berlin: Springer-Verlag.
15. Hu X, Lu Q, Kaplan DL, Cebe P. (2009). Microphase separation controlled α-sheet crystallization kinetics in fibrous proteins. Macromolecules, 42:2079.2087.
16. Richardson MJ, Savill NG. (1975). Derivation of accurate glasstransition temperatures by differential scanning calorimetry. Polymer, 16:753.757.
17. Hutchinson JM. (2009). Determination of the glass transition temperature: Methods correlation and structural heterogeneity. J Therm Anal Calorim, 98:579.589.
18. Cowie J M G, Ferguson R. (1989). Physical aging studies in poly (vinyl methyl ether). 1. Enthalpy relaxation as a function of aging temperature. Macromolecules, 22:2307.2312.
19. Airaksinen S, Karjalainen M, Shevchenko A, Westermarck S, Leppanen E, Rantanen J et al. (2005). Role of water in the physical stability of solid dosage formulations. J Pharm Sci, 94:2147.2165.
20. Pyda M, Wunderlich B. (2005). Reversing and nonreversing heat capacity of poly (lactic acid) in the glass transition region by temperature-modulated differential scanning calorimetry. Macromolecules, 38:10472.10479.
21. Craig DQ, Barsnes M, Royall PG, Kett VL. (2000). An evaluation of the use of modulated temperature DSC as a means of assessing the relaxation behaviour of amorphous lactose. Pharm Res, 17:696.700.